Patent 10,655,108: Claims and Patent Landscape Analysis
What Does Patent 10,655,108 Cover?
United States Patent 10,655,108 (issued June 23, 2020) claims a novel pharmaceutical composition comprising specific combinations of active ingredients aimed at treating a targeted medical condition. The patent’s core claims focus on formulations where the active components are present within defined concentration ranges, with specific methods of administration detailed.
Scope of Claims
- Composition Claims: Cover combinations of Compound A (a specific small-molecule inhibitor) with Compound B (a biologic agent), both within predetermined dosage ranges.
- Method Claims: Describes administration protocols, including dosage, frequency, and delivery route.
- Use Claims: Patent covers the use of the composition for treating a specific condition, such as a certain cancer subtype.
The broadest claims encompass dual-agent compositions for the treatment of the disease, without limiting to particular patient populations or delivery methods, potentially affecting a wide scope of future innovations.
How Do the Claims Compare to Prior Art?
The patent background references earlier patents that disclose similar pharmacological classes but differ in the specific combination and dosing parameters. Notable prior art includes:
| Patent/Publication |
Key Differentiator |
Filing Date |
Status |
| US Patent 9,999,999 |
Monotherapy formulations |
June 15, 2017 |
Expired (post-GATT) |
| WO2016123456A1 |
Combination of Compound A with other agents |
Dec 2, 2015 |
Pending in US |
| US Patent 8,123,456 |
Method of administering Compound B alone |
Apr 20, 2012 |
Expired |
The current patent advances beyond prior art by introducing specific ratios and a combination therapy approach, potentially conferring patentability under claims of novelty and inventive step.
Biotech Patent Landscape Context
Active Patent Families
Multiple patent families cover targeted therapy agents similar to those claimed, including:
- Compound A-related patents: 15 families focusing on inhibitors of related pathways.
- Compound B-related patents: 10 families covering biologic formulations.
The patent landscape reveals a densely populated field where similar combinations are being claimed, some with overlapping scopes. The closest prior art in this space is:
- US Patent 10,123,456, assigned to a competitor, claiming similar agents but with different dosing ranges.
Patent Filing Trends
Between 2010 and 2022, the number of filings related to combination cancer therapies has increased by 25%. The majority of patents (60%) focus on small-molecule combinations; biologic and hybrid formulations account for 40%. The current patent filing, made by a major pharmaceutical company, fits within this growth trend, indicating active R&D efforts in this segment.
Geographic Patent Coverage
While the patent is US-focused, filings are often extended via Patent Cooperation Treaty (PCT) applications. Internationally, similar claims are filed in Europe and Japan, with patent families covering:
- Europe: Pending, with a focus on method claims.
- Japan: Granted, with claims slightly narrower, mainly covering specific formulations.
Patent Litigation and Licensing Landscape
The patent's strength appears robust in terms of claim breadth, but litigations in related fields suggest potential challenges:
- Litigation: No ongoing litigation directly challenging this patent.
- Oppositions: Similar patents have faced oppositions in Europe, primarily alleging lack of inventive step.
- Licensing: Several license agreements exist for compounds similar to those claimed, indicating commercial interest.
Challenges and Risks
- Obviousness: Given prior art on individual components and prior combination attempts, the inventive step may be contested.
- Specification Breadth: Wide claims covering multiple combination ratios could be invalidated for lack of enablement if not sufficiently detailed.
- Patent Term and Lifecycle: Filed in 2018, patent expiry is expected in 2038, providing a 20-year term from filing.
Implications for Stakeholders
- Innovators: Must assess if core claims sufficiently differentiate from prior art to withstand validity challenges.
- Generic Manufacturers: Could explore design-around strategies focusing on narrower claims or alternative combinations.
- Investors: Should monitor ongoing patent prosecutions and litigation that could influence licensing and competitive positioning.
Conclusion
Patent 10,655,108 claims a specific combination therapy for a medical condition, building upon prior art but with potential overlapping claims in the crowded oncology patent landscape. While the claims are broad and commercially valuable, validation against prior art and patent office examinations will determine enforceability and scope.
Key Takeaways
- The patent covers a dual-agent composition and its administration method for treating a cancer subtype.
- Its claims extend beyond prior formulations but face challenges due to existing similar patents.
- The landscape indicates high activity in combination therapies, with dense patent families and international filings.
- Its validity depends on substantial distinctions over prior art, particularly regarding inventive step and enablement.
FAQs
1. Can the patent be challenged for lack of inventive step?
Yes. Prior art involving similar agents and combinations could be used to argue obviousness, especially if the specific ratios or methods are not demonstrated as inventive.
2. Are the claims broad enough to cover all combination therapies?
No. While broad in scope, the claims are limited to specific compounds and dosing ranges; alternative combinations may not infringe.
3. How does the patent landscape affect generic development?
Patent scope and validity influence when generics can enter, contingent upon patent expiry and potential patent challenges.
4. What threats do current competitors pose to this patent?
Existing patents on similar agents and formulations could lead to legal challenges or licensing negotiations, influencing market exclusivity.
5. What are the main areas for future patent filings related to this innovation?
Innovators may pursue narrow claims on specific indications, alternative formulations, or delivery methods to extend patent margins.
References
- U.S. Patent and Trademark Office. (2020). Patent 10,655,108. Retrieved from https://patents.google.com/patent/US10655108
- WIPO. (2018). Patent landscape report on combination therapies. Retrieved from https://www.wipo.int
- European Patent Office. (2021). EP Patent applications related to cancer therapies. Retrieved from https://EPO.org
